Arpeggio makes medicine to alter gene expression and fight drug resistance in cancer. We do this by combining CRISPR-engineer cell models, high throughput transcriptomics, and machine learning to discover novel chemistry against challenging targets. Arpeggio has partnered with top-tier Pharma companies like Pfizer & Janssen, and its pipeline contains a combination of first and best-in-class assets positioned against rare cancer types with high unmet need.